Related Experiment Video
Updated: Nov 10, 2025
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease
Neus Rabaneda-Lombarte1,2, Joan Serratosa1, Jordi Bové3
1Department of Cerebral Ischemia and Neurodegeneration, Institut d'Investigacions Biomèdiques de Barcelona-Consejo Superior de Investigaciones Científicas (CSIC), Institut d'Investigacions Biomèdiques August-Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Background:
It is suggested that neuroinflammation, in which activated microglial cells play a relevant role, contributes to the development of Parkinson's disease (PD). Consequently, the modulation of microglial activation is a potential therapeutic target to be taken into account to act against the dopaminergic neurodegeneration occurring in this neurological disorder. Several soluble and membrane-associated inhibitory mechanisms contribute to maintaining microglial cells in a quiescent/surveillant phenotype in physiological conditions. However, the presence of activated microglial cells in the brain in PD patients suggests that these mechanisms have been somehow overloaded. We focused our interest on one of the membrane-associated mechanisms, the CD200-CD200R1 ligand-receptor pair.
Methods:
The acute MPTP experimental mouse model of PD was used to study the temporal pattern of mRNA expression of CD200 and CD200R1 in the context of MPTP-induced dopaminergic neurodegeneration and neuroinflammation. Dopaminergic damage was assessed by tyrosine hydroxylase (TH) immunoreactivity, and neuroinflammation was evaluated by the mRNA expression of inflammatory markers and IBA1 and GFAP immunohistochemistry. The effect of the modulation of the CD200-CD200R1 system on MPTP-induced damage was determined by using a CD200R1 agonist or CD200 KO mice.
Results:
MPTP administration resulted in a progressive decrease in TH-positive fibres in the striatum and TH-positive neurons in the substantia nigra pars compacta, which were accompanied by transient astrogliosis, microgliosis and expression of pro- and anti-inflammatory markers. CD200 mRNA levels rapidly decreased in the ventral midbrain after MPTP treatment, while a transient decrease of CD200R1 mRNA expression was repeatedly observed in this brain area at earlier and later phases. By contrast, a transient increase in CD200R1 expression was observed in striatum. The administration of a CD200R1 agonist resulted in the inhibition of MPTP-induced dopaminergic neurodegeneration, while microglial cells showed signs of earlier activation in CD200-deficient mice.
Conclusions:
Collectively, these findings provide evidence for a correlation between CD200-CD200R1 alterations, glial activation and neuronal loss. CD200R1 stimulation reduces MPTP-induced loss of dopaminergic neurons, and CD200 deficiency results in earlier microglial activation, suggesting that the potentiation of CD200R1 signalling is a possible approach to controlling neuroinflammation and neuronal death in PD.
Insights
Neuroinflammation, involving microglial cells, contributes to Parkinson's disease (PD). Targeting the CD200-CD200R1 pathway shows potential for reducing dopaminergic neurodegeneration and controlling neuroinflammation in PD.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Neuroinflammation, driven by activated microglial cells, is implicated in Parkinson's disease (PD) pathogenesis.
- The CD200-CD200R1 ligand-receptor system is a key regulator of microglial cell activation.
- Dysregulation of these inhibitory mechanisms may contribute to the neurodegeneration observed in PD.
Purpose of the Study:
- To investigate the role of the CD200-CD200R1 pathway in MPTP-induced Parkinson's disease.
- To explore the therapeutic potential of modulating this pathway against dopaminergic neurodegeneration and neuroinflammation.
Main Methods:
- Utilized the MPTP mouse model for acute Parkinson's disease.
- Assessed dopaminergic damage via tyrosine hydroxylase (TH) immunoreactivity.
- Evaluated neuroinflammation through inflammatory marker mRNA expression and glial cell markers (IBA1, GFAP).
- Investigated the impact of CD200R1 agonist treatment and CD200 knockout (KO) on MPTP-induced effects.
Main Results:
- MPTP induced progressive dopaminergic neurodegeneration and transient neuroinflammation.
- CD200 mRNA levels decreased post-MPTP, while CD200R1 mRNA showed transient changes in specific brain regions.
- CD200R1 agonist administration protected against MPTP-induced dopaminergic neurodegeneration.
- CD200 deficiency led to earlier microglial activation.
Conclusions:
- Alterations in the CD200-CD200R1 system correlate with glial activation and neuronal loss in PD models.
- CD200R1 stimulation demonstrates neuroprotective effects against dopaminergic neuron loss.
- Potentiating CD200R1 signaling represents a promising therapeutic strategy for managing neuroinflammation and neuronal death in Parkinson's disease.
